HUP0303486A2 - 3,7-Diaza-biciklo-[3,3,1]-vegyületeket tartalmazó készítmények mint anti-aritmiás szerek - Google Patents

3,7-Diaza-biciklo-[3,3,1]-vegyületeket tartalmazó készítmények mint anti-aritmiás szerek

Info

Publication number
HUP0303486A2
HUP0303486A2 HU0303486A HUP0303486A HUP0303486A2 HU P0303486 A2 HUP0303486 A2 HU P0303486A2 HU 0303486 A HU0303486 A HU 0303486A HU P0303486 A HUP0303486 A HU P0303486A HU P0303486 A2 HUP0303486 A2 HU P0303486A2
Authority
HU
Hungary
Prior art keywords
compounds
diaza
oxa
bicyclo
arrythmic
Prior art date
Application number
HU0303486A
Other languages
English (en)
Inventor
Christina Hovdal
Anna Lundgren
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0303486A2 publication Critical patent/HUP0303486A2/hu
Publication of HUP0303486A3 publication Critical patent/HUP0303486A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgya azonnali hatóanyag-felszabadulású gyógyászatikészítmény, ami hatóanyagként 4-({3-[7-(3,3-dimetil-2- oxo-butil)-9-oxa-3,7-diaza-biciklo[3,3,1)non-3-il)-propil}-amino)- benzonitrilt, 2-{7-[3-(4-ciano-anilino)-propil)-9-oxa-3,7-diaza-biciklo[3,3,1)non-3-il}-etil-karbaminsav-terc-butil-észtert, 3-{7-[4- (4-ciano-fenil)-butil]-9-oxa-3,7-diaza-biciklo[3,3,1]non- 3-il}-etil-karbaminsav-terc-butil-észtert vagy 2-{7-[(2S)-3- (4-ciano-fenoxi)- 2-hidroxi-propil]-9-oxa-3,7-diaza-biciklo[3,3,1]non-3-il}-etil-karbaminsav-terc-butil-észtert vagy a felsoroltak bármelyikének gyógyászatilag alkalmazhatósóját tartalmazza, gyógyászatilag elfogadható hígítószerrel vagyhordozóanyaggal együtt. Ó
HU0303486A 2001-04-12 2002-04-12 Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anti-arrythmic compounds agents HUP0303486A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101329A SE0101329D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation
PCT/SE2002/000726 WO2002083689A1 (en) 2001-04-12 2002-04-12 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds

Publications (2)

Publication Number Publication Date
HUP0303486A2 true HUP0303486A2 (hu) 2004-01-28
HUP0303486A3 HUP0303486A3 (en) 2005-04-28

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303486A HUP0303486A3 (en) 2001-04-12 2002-04-12 Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anti-arrythmic compounds agents

Country Status (26)

Country Link
US (1) US20050037067A1 (hu)
EP (1) EP1389212B1 (hu)
JP (1) JP2005500262A (hu)
KR (1) KR20030088498A (hu)
CN (1) CN1514839A (hu)
AR (1) AR035806A1 (hu)
AT (1) ATE332902T1 (hu)
BG (1) BG108234A (hu)
BR (1) BR0208828A (hu)
CA (1) CA2443473A1 (hu)
CZ (1) CZ20032774A3 (hu)
DE (1) DE60213084T2 (hu)
EE (1) EE200300495A (hu)
HU (1) HUP0303486A3 (hu)
IL (1) IL158033A0 (hu)
IS (1) IS6989A (hu)
MX (1) MXPA03009209A (hu)
NO (1) NO20034529L (hu)
NZ (1) NZ528561A (hu)
PL (1) PL366629A1 (hu)
RU (1) RU2003129230A (hu)
SE (1) SE0101329D0 (hu)
SK (1) SK12562003A3 (hu)
TW (1) TWI257391B (hu)
WO (1) WO2002083689A1 (hu)
ZA (1) ZA200307756B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
AU2006329006B2 (en) * 2005-12-20 2013-02-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2979698A4 (en) * 2013-03-29 2016-11-16 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
AU774526B2 (en) * 1999-04-09 2004-07-01 Astrazeneca Ab Adamantane derivatives
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
NO20034529D0 (no) 2003-10-09
WO2002083689A1 (en) 2002-10-24
AR035806A1 (es) 2004-07-14
EP1389212A1 (en) 2004-02-18
PL366629A1 (en) 2005-02-07
NO20034529L (no) 2003-12-08
CN1514839A (zh) 2004-07-21
BR0208828A (pt) 2004-03-09
CA2443473A1 (en) 2002-10-24
JP2005500262A (ja) 2005-01-06
HUP0303486A3 (en) 2005-04-28
RU2003129230A (ru) 2005-04-10
SE0101329D0 (sv) 2001-04-12
DE60213084T2 (de) 2007-01-11
SK12562003A3 (sk) 2004-03-02
IL158033A0 (en) 2004-03-28
BG108234A (bg) 2005-04-30
EE200300495A (et) 2003-12-15
MXPA03009209A (es) 2004-01-29
CZ20032774A3 (cs) 2004-01-14
ATE332902T1 (de) 2006-08-15
DE60213084D1 (de) 2006-08-24
NZ528561A (en) 2005-03-24
IS6989A (is) 2003-10-10
TWI257391B (en) 2006-07-01
KR20030088498A (ko) 2003-11-19
ZA200307756B (en) 2005-01-03
US20050037067A1 (en) 2005-02-17
EP1389212B1 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
NL300877I2 (nl) obeticholzuur
EP1939175A4 (en) SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
HUP0303487A2 (hu) 3,7-Diaza-biciklo[3,3,1]-vegyületeket tartalmazó készítmények mint anti-aritmiás szerek és eljárás a vegyületek előállítására
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
AP1739A (en) Azaindoles
NL300298I1 (nl) Nieuwe 3-piperidinyl-1,2-benzisoxazolen
RS51436B (en) DERIVATIVES TRIAZOLIL TROPANA KAO MODULATORS CCR5
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
WO2002048148A3 (en) Pyrazolopyridine derivatives
MXPA03011998A (es) Pirrolopirimidinas como inhibidores de protein cinasa.
EP0309043A3 (en) Novel substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
HUP0303486A2 (hu) 3,7-Diaza-biciklo-[3,3,1]-vegyületeket tartalmazó készítmények mint anti-aritmiás szerek
MA29969B1 (fr) Formulations de quinolinones
CA2254755A1 (en) Hexahydro-pyrido(4,3-b)indole derivatives as antipsychotic drugs
HUP0303481A2 (hu) 3,7-Diaza-biciklo-[3,3,1] vegyületeket tartalmazó készítmények mint anti-aritmiás szerek
CA2292921A1 (en) Aryl carboxylic acid and tetrazole derivatives
WO2004089943A8 (en) Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues
WO2002038563A3 (en) Condensed pyrazindione derivatives as pde inhibitors
MY138657A (en) broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
EA200400864A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ
DK1010694T3 (da) Spiroimidazolinderivater og deres anvendelse som alfa2-adrenerge antagonister og monoamin-genoptagningsblokkere
MXPA04000188A (es) Azaindoles.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees